Zoetis Appoints Paul M. Bisaro to Board of Directors
April 13 2015 - 8:30AM
Business Wire
Zoetis Inc. (NYSE:ZTS) today announced that its Board of
Directors has appointed Paul M. Bisaro, Executive Chairman of
Actavis plc, to the company’s Board of Directors. Mr. Bisaro’s term
will begin immediately following the company’s 2015 Annual Meeting
of Shareholders, which is scheduled for May 1, 2015. With the
addition of Mr. Bisaro, the Zoetis Board will expand to 11
directors, and he will serve on the Compensation Committee.
“We are pleased to announce that Paul will join the Zoetis
Board,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “He
brings extensive business leadership and global healthcare
experience to Zoetis, along with a deep understanding of the
pharmaceutical industry. He will be a valuable addition to our
board as we continue to grow our position as the world’s leading
animal health company.”
Mr. Bisaro has more than 20 years of experience in the
healthcare industry. He is Executive Chairman of Actavis plc, a
global pharmaceutical company focused on developing, manufacturing
and commercializing innovative branded pharmaceuticals,
high-quality generic and over-the-counter medicines, and biologic
products.
He previously served as President, CEO and Chairman of the Board
of Actavis. Prior to joining Actavis (then Watson Pharmaceuticals),
he was President and Chief Operating Officer of Barr
Pharmaceuticals, Inc. He also served as General Counsel at Barr and
held various additional roles, including Senior Vice President of
Strategic Business Development. Prior to joining Barr, Mr. Bisaro
was associated with the law firm Winston & Strawn and a
predecessor firm, Bishop, Cook, Purcell and Reynolds. He also
served as a Senior Consultant with Arthur Andersen & Co.
About Zoetis
Zoetis (zô-EH-tis) is the leading animal health company,
dedicated to supporting its customers and their businesses.
Building on more than 60 years of experience in animal health,
Zoetis discovers, develops, manufactures and markets veterinary
vaccines and medicines, complemented by diagnostic products and
genetic tests and supported by a range of services. In 2014, the
company generated annual revenue of $4.8 billion. With
approximately 10,000 employees worldwide at the beginning of 2015,
Zoetis serves veterinarians, livestock producers and people who
raise and care for farm and companion animals with sales of its
products in 120 countries. For more information, visit
www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains
forward-looking statements, which reflect the current views of
Zoetis with respect to business plans or prospects, future
operating or financial performance, expectations regarding
products, future use of cash and dividend payments, and other
future events. These statements are not guarantees of future
performance or actions. Forward-looking statements are subject to
risks and uncertainties. If one or more of these risks or
uncertainties materialize, or if management's underlying
assumptions prove to be incorrect, actual results may differ
materially from those contemplated by a forward-looking statement.
Forward-looking statements speak only as of the date on which they
are made. Zoetis expressly disclaims any obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2014, including in the sections thereof captioned
“Forward-Looking Information and Factors That May Affect Future
Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on
Form 10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online at www.sec.gov,
www.zoetis.com, or on request from Zoetis.
Zoetis Inc.Media:Bill Price, 1-973-443-2742
(o)william.price@zoetis.comorElinore White, 1-973-443-2835
(o)elinore.y.white@zoetis.comorInvestors:John O'Connor,
1-973-822-7088 (o)john.oconnor@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024